|Bid||2.4000 x 1000|
|Ask||2.6000 x 800|
|Day's Range||2.3700 - 2.5250|
|52 Week Range||2.2700 - 13.1100|
|Beta (3Y Monthly)||2.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.38|
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.
CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The ascendancy of the biotech stock market to where it is today has only been made possible by the fact that biotech companies continue to formulate and manufacture top-of-the-line technologies for the purpose of the betterment of the human experience. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ImmunoGen Inc (IMGN), Tenax Therapeutics Inc (NASDAQ:TENX) and 22nd Century Group Inc (NYSE American: XXII) are four biotech companies focused on investing in the future of humanity. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is leading the healthcare industry in developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to create a patient-centric healthcare framework.
Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.
Why ImmunoGen Tanked on FridayStock price movements On March 1, ImmunoGen (IMGN) closed at $2.51, 46.82% lower than its previous closing price. At the end of Friday, the company had a market capitalization of $369.52 million. The dramatic drop in
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. Warning! GuruFocus has detected 4 Warning Signs with IMGN. For the last quarter Immunogen Inc reported a revenue of $13.8 million, compared with the revenue of $39.45 million during the same period a year ago.
was down more than 45% in trading Friday after the company's ovarian cancer treatment candidate failed to meet the primary endpoint in a phase 3 trial. The trial evaluated the efficacy of its treatment candidate compared to the results of treatment with chemotherapy in patients with folate receptor alpha positive, platinum-resistant ovarian cancer. "Even though FORWARD I did not meet its primary endpoint, I continue to be impressed with the efficacy and tolerability of mirvetuximab soravtansine in ovarian cancer patients, especially in the subset with high FRα expression," said Dr. Kathleen Moore, associate director of clinical research at the Stephenson Cancer Center at the University of Oklahoma.
The drugmaker, which has more than 200 employees, reported Friday morning that its ovarian cancer drug failed to lead to a longer survival rate without the cancer spreading.
Shares of Immunogen Inc. plummeted 48% toward a two-year low in premarket trade Friday, after the company said a phase 3 trial of its ovarian cancer treatment, mirvetuximab soravtansine, compared to chemotherapy, failed to meet its primary endpoint of progression free survival. The company said that based on the efficacy signals, overall response rate and survival, it will conduct additional analysis to evaluation the potential benefit of mirvetuximab soravtansine for FRα-positive platinum-resistant ovarian cancer. "ImmunoGen is in a strong financial position with approximately $295 million in cash on our balance sheet, and we will continue to advance our portfolio of next-generation ADCs, which includes three additional development candidates targeting a range of tumor types in both hematologic malignancies and solid tumors," said Chief Executive Mark Enyedy. The stock has tumbled 57% over the past 12 months through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 5.3% and the S&P 500 has tacked on 4.0%.
U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study. When compared with chemotherapy, the drug, mirvetuximab soravtansine, ...
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.
WALTHAM, Mass.-- -- Continued Innovation in ADCs Highlighted in Eleven Posters First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers Novel DARPin ® Drug Conjugate Platform Evaluated in Collaboration with Molecular Partners AG ImmunoGen, Inc. , , a leader in the expanding ...
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! ImmunoGen, Inc. (NASDAQ:IMGN) is a company with exceptional fundamental characteristics.Read More...
ImmunoGen (IMGN) delivered earnings and revenue surprises of 15.15% and 14.97%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?